52 Results

People

  1. Yahalom
    Yahalom
  2. Zelenetz
    Zelenetz
  3. Hamlin
    Hamlin
  4. Horwitz
    Horwitz
  5. Noy
    Noy
  6. Moskowitz
    Moskowitz
  7. Palomba
    Palomba
  8. Kumar
    Kumar
  9. Matasar
    Matasar
  10. Schoder
    Schoder

Groups

  1. Center for Hematologic Malignancies (52)
  2. Department of Medicine (52)
  3. Hematologic Malignancies, Division of (52)
  4. Lymphoma (52)
  5. Radiation Oncology, Department of (52)
  6. Survivorship Research (52)
  7. Population Sciences Research Program (41)
  8. Molecular Imaging and Therapy Service (30)
  9. Radiology, Department of (30)
  10. Epidemiology and Biostatistics (22)
  1. "Radiation Oncology, Department of"
  2. "Paul Hamlin"
Formats
  1. Meeting Abstract (29)
  2. Journal Article (22)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (52)
  2. Department of Medicine (52)
  3. Hematologic Malignancies, Division of (52)
  4. Lymphoma (52)
  5. Radiation Oncology, Department of (52)
  6. Survivorship Research (52)

More Groups

People
  1. Joachim Yahalom (52)
  2. Paul Hamlin (52)
  3. Andrew Zelenetz (50)
  4. Ariela Noy (41)
  5. Steven Horwitz (41)
  6. David Straus (39)

More People

Years
  1. 2024 (1)
  2. 2023 (7)
  3. 2022 (3)
  4. 2021 (7)
  5. 2020 (4)
  6. 2019 (5)

More Years

Publications
  1. Blood (24)
  2. Hematological Oncology (7)
  3. Blood Advances (4)
  4. British Journal of Haematology (4)
  5. Journal of Clinical Oncology (3)
  6. Haematologica (2)

More Publications

Publishers
  1. American Society of Hematology (28)
  2. Wiley Blackwell (7)
  3. John Wiley & Sons (4)
  4. American Society of Clinical Oncology (3)
  5. Elsevier Inc. (2)
  6. Ferrata Storti Foundation (2)

More Publishers

Results (52)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Distinct patterns of CD4+and CD8+ T-cell clonal expansion enable broad clinical responses to pembrolizumab + GVD in patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Rahman, J.; Ganesan, N.; Shah, G. L.; Noy, A.; Schoder, H.; Yahalom, J.; Kumar, A.; Falchi, L.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save